Fortune December 10, 2024
Tavapadon, a drug being tested to treat early Parkinson’s disease, has shown great promise in a Phase III trial by AbbVie, the pharmaceutical company announced this week.
Parkinson’s disease, which is lifelong, progressive and has no cure, occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die, according to the Michael J. Fox Foundation for Parkinson’s Research. This causes tremors,...